More ADAURAble by the day.

The results of ADAURA were reported at ASCO 2020 and showed an impressive improvement in disease free survival (52→ 89% at 24 months) when maintenance osimertinib was given to patients with resected, EGFR-mutated NSCLC. These results have now been published in manuscript form and additional exploratory analysis of recurrence patterns were presented at ESMO 2020. The big news this time was the CNS activity. Even though the number of events was small, 2% of patients on osimertinib had CNS events compared to 11% with placebo (an 82% relative reduction in the risk of CNS disease or death). TBL: The impressive benefit of maintenance osimertinib for resected, non-metastatic NSCLC also appears to reduce the risk of CNS recurrence. | Wu, N Engl J Med 2020 (ESMO 2020)